Organ Transplantation | Natera


New ProActive Registry: largest clinical utility study evaluating Prospera in >3K kidney transplant patients


Get a blood draw in the comfort of your own home.


Natera uses revolutionary technology to enhance the patient and physician's ability to assess otherwise undetected rejection events that might lead to loss of the transplanted organ.


In the U.S., the most commonly transplanted organs include kidneys, livers and hearts. Chronic Kidney Disease, or CKD, affects roughly 14% of Americans. It progresses through five stages, the final one being kidney failure. More than 660,000 Americans are experiencing kidney failure; of these people, the majority are on dialysis and another 190,000 live with a functioning organ transplant.

Every year, about 20,000 people receive kidney transplants. However, 50% of these procedures prove unsuccessful within ten years, and 20-30% fail within the first five. The most common reason these operations flounder is because the signs of organ rejection aren’t caught early enough to be treated effectively. When a body part is rejected, the patient may need another transplant and must begin the waitlist process again.

If organ rejection can be caught earlier, it can be treated immediately, increasing the odds that the patient can continue to use the donated kidney.


Personalizing chronic kidney disease

Comprehensive genetic panel to inform and tailor management strategies.


Track the health of your transplanted organ

Prospera is optimized to be the most precise cfDNA tool for early, clinically meaningful rejection assessment.

Our Transplant Test

Prospera provides organ transplant services by using proprietary cfDNA technology to monitor signs of active rejection. The evaluation is conducted via a blood test, which is less invasive than a biopsy.

Currently, the baseline screening standard is a serum creatine test. However, Prospera is a more accurate assessment, since a serum creatine test cannot reveal a kidney transplant injury. The research on Prospera also indicates higher performance compared to other first generation cfDNA and serum creatine tests. This means that Prospera produces more precise, reliable information to help detect rejection earlier.

Natera: Providing Testing to Help Identify Organ Rejection

At Natera, our extensive experience in cfDNA and proprietary bioinformatics provides you with highly accurate results. Our cutting-edge technology can alert you to signs of organ rejection early, so that you can treat it immediately and improve your chance of a successful kidney transplant. Talk to a doctor about whether Prospera is right for you.


Listen to our founder, Matthew Rabinowitz Ph.D., talk about his experience starting Natera and discovering applications of cell-free DNA in pregnancy, cancer, and now transplantation.


Natera announces agreement with OneLambda to co-distribute Prospera transplant assessment test.

Learn More